Prognostic Significance of Tracking Dynamic Changes in Positron Emission Tomography (PET) Scan Pre and Post Autologous Stem Cell Transplant (ASCT)

CONCLUSIONS:Negative PET-CT imaging post ASCT is associated with better OS and PFS. Also, in our population, the absence of positive FL by PET-CT scan in newly diagnosed MM patients pre and post ASCT shows a trend towards better PFS and OS. Clearance of FL by PET scan trends towards improved PFS and OS. Longer follow up is needed to declare statistical significance between those cohorts.Figure.DisclosuresAtrash: Takeda Oncology: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Membership on an entity's Board of Directors or advisory committees. Voorhees: Amgen Inc.: Speakers Bureau; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: served on an IRC; Novartis: Consultancy, Other: served on an IRC; TeneoBio: Consultancy, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: served on an IRC. Avalos: Juno: Membership on an entity's Board of Directors or advisory committees. Usmani: Amgen, BMS, Celgene, Janssen, Merck, Pharmacyclics,Sanofi, Seattle Genetics, Takeda: Research Funding; Abbvi...
Source: Blood - Category: Hematology Authors: Tags: 651. Myeloma: Biology and Pathophysiology, excluding Therapy Source Type: research